Johnson & Johnson (NYSE:JNJ) Stifel 2024 Healthcare Conference November 18, 2024 10:55 AM ET
Company Participants
Michael Bodner - Group President, Heart Recovery and Circulatory Restoration
Conference Call Participants
Rick Wise - Stifel
Rick Wise
Okay everybody, Rick Wise again here and it is my pleasure and truly my privilege to welcome J&J to the 2024 Stifel Healthcare Conference. To my left, Michael Bodner, Group President, Heart Recovery and Circulatory Restoration. In the audience, two friends from Investor Relations, Alec Mast and the wonderful Tracy Menkowski. Welcome to you both as well. Michael Bodner has led both the Abiomed and Shockwave franchises and just for perspective, it's about 3.5% or so of J&J total sales at this point since their acquisitions in December of '22 and May 2024, respectively.
Michael Bodner has led both the Abiomed and Shockwave franchises and just for perspective, it's about 3.5% or so of J&J total sales at this point. Since their acquisitions in December of '22 and May 2024, respectively. And Michael is a seasoned interventional cardiology exec, 15 years plus experience and was previously Worldwide President of J&J's global, leading, amazing, Biosense Webster, EP business. It is a known fact that I went to Israel before they ever came -- or near J&J and visited Shlomo. Way back. That's way back.
Michael Bodner
Back when it was in Yokne'am -- no, Haifa, then move to Yokne'am.
Question-and-Answer Session
Q - Rick Wise
So Michael, I was at TCT and I just thought we'd start off with some post-TCT reflections. J&J spent $30 billion to bring both Shockwave and Abiomed under the J&J umbrella. With these two companies inside, I noticed that J&J had a huge presence at TCT on the floor in the clinical sessions. Just wondered -- just since we didn't get a chance to meet there, what were your impressions
- Read more current JNJ analysis and news
- View all earnings call transcripts